| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Real-World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database. |
| 掲載誌名 | 正式名：Neuropsychopharmacology reports 略 称：Neuropsychopharmacol Rep ISSNコード：2574173X/2574173X |
| 掲載区分 | 国外 |
| 巻・号・頁 | 46(2),pp.e70133 |
| 著者・共著者 | Masaki Kato, Tatsuya Hoshino, Yayoi Kawata, Fumie Tokuda, Shinji Fujimoto |
| 発行年月 | 2026/06 |
| 概要 | AIM:Vortioxetine has been approved for the treatment of patients with major depressive disorder (MDD) in Japan since 2019; however, limited data are available on its use in clinical practice. This study aimed to identify real-world prescribing patterns for first-line antidepressant treatment of patients with MDD in Japan, and to understand how patient characteristics influence treatment selection and continuation.METHODS:This retrospective cohort study utilized data from the JMDC claims database. Patients with MDD (aged ≥ 18 years) were included if they were newly prescribed antidepressants between November 1, 2019 and May 31, 2024. The primary outcome was the distribution of antidepressants prescribed as first-line treatment. Secondary outcomes included evaluating treatment patterns and characteristics among patients receiving a single antidepressant as first-line therapy.RESULTS:The analysis population included 263 773 patients, of whom 97.4% had single-drug prescriptions (vortioxetine [10.2%], selective serotonin reuptake inhibitors [48.3%], serotonin-norepinephrine reuptake inhibitors [15.2%], noradrenergic and specific serotonergic antidepressants [9.8%], and other antidepressants [13.9%]), and 2.6% had multiple-drug prescriptions. Patients were less likely to be prescribed vortioxetine if they were female (odds ratio: 0.802; 95% confidence interval: 0.781-0.824) or older than 60 years (0.544; 0.498-0.594), whereas patients with somnolence (2.248; 1.152-4.385), adjustment disorders (1.488; 1.433-1.544), and nausea and vomiting (1.253; 1.194-1.315) were more likely to be prescribed vortioxetine. In the first 3 months after initiating vortioxetine treatment, 41.3% of patients continued treatment, 44.7% discontinued, and 14.0% changed treatment. Treatment change was more common in women (1.129; 1.046-1.218), and in patients with physical symptoms, whereas mental health-related comorbidities were associated with treatment persistence.CONCLUSION:These findings suggest that vortioxetine is more commonly prescribed to working-age men in Japan, and that patient characteristics and tolerability considerations contribute to prescribing and continuation patterns in clinical practice. |
| DOI | 10.1002/npr2.70133 |
| PMID | 42234570 |